Cargando…
Add‐on cannabidiol significantly decreases seizures in 3 patients with SYNGAP1 developmental and epileptic encephalopathy
Mutations in SYNGAP1 are associated with developmental delay, epilepsy, and autism spectrum disorder (ASD). Epilepsy is often drug‐resistant in this syndrome with frequent drop attacks. In a prospective study of add‐on cannabidiol (CBD), we identified three patients with SYNGAP1 mutations: two boys...
Autores principales: | Kuchenbuch, Mathieu, D'Onofrio, Gianluca, Chemaly, Nicole, Barcia, Giulia, Teng, Théo, Nabbout, Rima |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469777/ https://www.ncbi.nlm.nih.gov/pubmed/32913957 http://dx.doi.org/10.1002/epi4.12411 |
Ejemplares similares
-
Slow Titration of Cannabidiol Add-On in Drug-Resistant Epilepsies Can Improve Safety With Maintained Efficacy in an Open-Label Study
por: D'Onofrio, Gianluca, et al.
Publicado: (2020) -
SYNGAP1 encephalopathy: A distinctive generalized developmental and epileptic encephalopathy
por: Vlaskamp, Danique R.M., et al.
Publicado: (2019) -
Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1
por: Carvill, Gemma L., et al.
Publicado: (2013) -
Phenotypes in Children With SYNGAP1 Encephalopathy in China
por: Zhang, Huiting, et al.
Publicado: (2021) -
Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial
por: Scheffer, Ingrid E., et al.
Publicado: (2021)